Please assess the completion status of the following clinical trial:

Trial Title: Study to Assess the Safety of Dupilumab (REGN668/SAR231893) Administered Concomitantly With Topical Corticosteroids (TCS) in Patients With Moderate-to-severe Atopic Dermatitis (AD)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Male and female patients aged 18 years or older~2. Chronic AD that had been present for at least 2 years~Exclusion Criteria:~1. Prior treatment with Dupilumab~2. Hypersensitivity to corticosteroids or to any other ingredients contained by the TCS product used in the study~3. AD lesions located on face, flexural, and genital areas~4. Certain treatments and medical procedures, undertaken within a particular time frame prior to the baseline visit, preclude eligibility for participation in the study~5. Treatment with a live (attenuated) vaccine within 12 weeks before the baseline visit~6. Treatment with an investigational drug within 8 weeks~7. Known history of human immunodeficiency virus (HIV) infection~8. Presence of certain laboratory abnormalities at the screening visit~9. History of certain opportunistic infections or certain clinical parasite infections~10. History of malignancy within 5 years before the baseline visit, with certain exceptions~11. Pregnant or breast-feeding women~12. Travel within 12 months of study start to areas endemic for parasitic infections, such as developing countries in Africa and the tropical and subtropical regions of Asia~13. History of alcohol or drug abuse within 2 years of the screening visit~14. Any medical or psychiatric condition which, in the opinion of the investigator or the sponsor's medical monitor, would place the patient at risk, interfere with participation in the study, or interfere with the interpretation of study results

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Placebo QW (Type: EXPERIMENTAL): Placebo (for Dupilumab) once weekly (QW) for 4 weeks by subcutaneous injection with the background therapy of potent topical corticosteroid (TCS) for up to 28 days
- Dupilumab 300 mg QW (Type: EXPERIMENTAL): Dupilumab 300 mg once weekly (QW) for 4 weeks by subcutaneous injection with the background therapy of potent TCS for up to 28 days

Based on this trial design, predict the completion outcome and termination type (if applicable).